Abstract
ER negative and Triple negative breast cancers carry a poorer prognosis and are not amenable to hormone therapy. It has been previously observed that Indian patients with breast cancer have a higher tendency to have these tumours. Whether this is due to inherent biological differences in the tumours of our patients is a matter of much debate. We have analysed 250 patients of breast cancer for hormone receptor status, compared them with western series, and attempted to support the hypothesis that the higher ER negativity and triple negativity is indeed due to different tumour biology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: available at www.seer.cancer.gov
Shet T, Agrawal A, Nadkarni M et al (2009) Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol 52(2):171–174
Kuraparthy S, Reddy KM, Yadagiri LA et al (2007) Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol 5:56
Dey S, Boffetta P, Mathews A et al. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer. 2009 Oct 1;125(7):1663–1670
Eifel P, Axelson JA, Costa J et al (2001) National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979–989
Goldstein NS, Ferkowicz M, Odish E et al (2003) Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86–92
Rhodes A, Jasani B, Balaton AJ et al (2001) Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 115:44–58
Vassallo J, Pinto GA, Alvarenga M et al (2004) Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl Immunohistochem Mol Morphol 12:177–182
Umemura S, Itoh J, Itoh H et al (2004) Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol 12:8–13
Navani S, Bhaduri AS (2005) High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction? Indian J Pathol Microbiol 48:199–201
Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF (2009) Hormone receptor status of breast cancer in India: a study of 798 tumors. Breast 9:267–70
Raina V, Bhutani M, Bedi R et al (2005) Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Indian J Cancer 42(1):40–5
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manjunath, S., Prabhu, J.S., Kaluve, R. et al. Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype?. Indian J Surg Oncol 2, 122–125 (2011). https://doi.org/10.1007/s13193-011-0072-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-011-0072-8